A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Arcus Biosciences, Inc.
Duke University
USWM, LLC (dba US WorldMeds)
Amgen
Novartis
Ohio State University Comprehensive Cancer Center
University Health Network, Toronto
NeoTX Therapeutics Ltd.
Astellas Pharma Inc
Immunitas Therapeutics
Sichuan Baili Pharmaceutical Co., Ltd.
Jonsson Comprehensive Cancer Center
Cancer Research UK
Tempus AI
Cybrexa Therapeutics
NextCure, Inc.
Revolution Medicines, Inc.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Adaptimmune